Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

Clinical trial NCT00538694 · COMPLETED

Trial details

NCT number: NCT00538694
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Pneumonia, Bacterial

Start date: 2000-10-31
Primary completion: 2001-09-30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.